Aarti S. Zanwar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aarti S. Zanwar has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Dhanya B. Sen
Department of Pharmacy Sumandeep Vidyapeeth Deemed to be University Vadodara Gujarat India
4 shared publications Ashim Kumar Sen
Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, At and Po. Piparia, Vadodara, Gujarat, India
2 shared publications- Rajesh A. Maheshwari
Department of Pharmacy Sumandeep Vidyapeeth Deemed to be University Vadodara Gujarat India
2 shared publications Ashim K. Sen
Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Waghodia, Vadodara – 391760, Gujarat
1 shared publication- Ashim Kumar Sen
Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Waghodia, Vadodara-391760, Gujarat, India
1 shared publication - Chintan Aundhia
Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Waghodia, Vadodara, 391760, Gujarat, India
1 shared publication
Latest Publications
- 1 February 2025
- Published by Bentham Science Publishers Ltd. in Pharmaceutical Nanotechnology
- Vol. 13 (1) , 55-69
Enhancing Gene Therapy through Ultradeformable Vesicles for Efficient siRNA Delivery
Gene therapy is a revolutionary approach aimed at treating various diseases by manipulating the expression of specific genes. The composition and formulation of ultra-deformable vesicles play a crucial role in determining their properties and performance as siRNA delivery vectors. In the development of ultra-deformable vesicles for siRNA delivery, careful lipid selection and optimization are crucial for achieving desirable vesicle characteristics and efficient siRNA encapsulation and delivery. The stratum corneum acts as a protective barrier, limiting the penetration of molecules, including siRNA, into the deeper layers of the skin. Ultradeformable vesicles offer a promising solution to overcome this barrier and facilitate efficient siRNA delivery to target cells in the skin. The stratum corneum, the outermost layer of the skin, acts as a significant barrier to the penetration of siRNA.These engineering approaches enable the production of uniform and well-defined vesicles with enhanced deformability and improved siRNA encapsulation efficiency. Looking ahead, advancements in ultra-deformable vesicle design and optimization, along with continued exploration of combination strategies and regulatory frameworks, will further drive the field of ultra-deformable vesicle-based siRNA delivery.
- 1 February 2025
- Published by Bentham Science Publishers Ltd. in Pharmaceutical Nanotechnology
- Vol. 13 (1) , 55-69
Enhancing Gene Therapy through Ultradeformable Vesicles for Efficient siRNA Delivery
Gene therapy is a revolutionary approach aimed at treating various diseases by manipulating the expression of specific genes. The composition and formulation of ultra-deformable vesicles play a crucial role in determining their properties and performance as siRNA delivery vectors. In the development of ultra-deformable vesicles for siRNA delivery, careful lipid selection and optimization are crucial for achieving desirable vesicle characteristics and efficient siRNA encapsulation and delivery. The stratum corneum acts as a protective barrier, limiting the penetration of molecules, including siRNA, into the deeper layers of the skin. Ultradeformable vesicles offer a promising solution to overcome this barrier and facilitate efficient siRNA delivery to target cells in the skin. The stratum corneum, the outermost layer of the skin, acts as a significant barrier to the penetration of siRNA.These engineering approaches enable the production of uniform and well-defined vesicles with enhanced deformability and improved siRNA encapsulation efficiency. Looking ahead, advancements in ultra-deformable vesicle design and optimization, along with continued exploration of combination strategies and regulatory frameworks, will further drive the field of ultra-deformable vesicle-based siRNA delivery.
- 24 June 2024
- Published by Elsevier in Current Pharmaceutical Analysis
- Vol. 20 (5) , 345-357
Synchronized Assessment of Lobeglitazone Sulfate and Metformin Hydrochloride in Tablet by Robust, High-performance Thin-layer Chromatographic Method
Background: A combination of fixed-doses containing 0.5 mg lobeglitazone sulfate and 500 mg metformin hydrochloride has demonstrated efficacy in enhancing glycemic control in diabetes. Aims: The projected work aimed to establish and validate a high-performance thin-layer chromatographic methodology for the quantification of both drugs in tablet formulations. Objectives: The task involves creating and validating a method in accordance with ICH guidelines to quantify two particular drugs in tablet formulations accurately. Methods: The high-performance thin-layer chromatographic analysis utilized aluminum plates layered with silica gel 60F254, and the solvent system consisted of acetonitrile, 1 M ammonium acetate (methanol), toluene, and triethyl amine (1.5:2.5:4:0.2 v/v/v/v), followed by densitometric scanning at 237 nm. Results: The methodology exhibited linearity in the range of 100-1500 ng/band for lobeglitazone sulfate and 1000-15000 ng/band for metformin hydrochloride, with correlation coefficients of 0.9991 and 0.9992, correspondingly. Exceptional sensitivity was observed, with detection limits of 8.17 ng/band for lobeglitazone sulfate and 271.34 ng/band for metformin hydrochloride, along with quantification limits of 24.75 ng/band for lobeglitazone sulfate and 822.24 ng/band for metformin hydrochloride. The method demonstrated precision (% relative standard deviation of peak area <2) and accuracy (recovery between 96 and 103%). Conclusion: The suggested methodology is fit for the concurrent quantification of both drugs in tablet formulations, making it applicable for routine quality control assessments in laboratories.
- 24 June 2024
- Published by Elsevier in Current Pharmaceutical Analysis
- Vol. 20 (5) , 345-357
Synchronized Assessment of Lobeglitazone Sulfate and Metformin Hydrochloride in Tablet by Robust, High-performance Thin-layer Chromatographic Method
Background: A combination of fixed-doses containing 0.5 mg lobeglitazone sulfate and 500 mg metformin hydrochloride has demonstrated efficacy in enhancing glycemic control in diabetes. Aims: The projected work aimed to establish and validate a high-performance thin-layer chromatographic methodology for the quantification of both drugs in tablet formulations. Objectives: The task involves creating and validating a method in accordance with ICH guidelines to quantify two particular drugs in tablet formulations accurately. Methods: The high-performance thin-layer chromatographic analysis utilized aluminum plates layered with silica gel 60F254, and the solvent system consisted of acetonitrile, 1 M ammonium acetate (methanol), toluene, and triethyl amine (1.5:2.5:4:0.2 v/v/v/v), followed by densitometric scanning at 237 nm. Results: The methodology exhibited linearity in the range of 100-1500 ng/band for lobeglitazone sulfate and 1000-15000 ng/band for metformin hydrochloride, with correlation coefficients of 0.9991 and 0.9992, correspondingly. Exceptional sensitivity was observed, with detection limits of 8.17 ng/band for lobeglitazone sulfate and 271.34 ng/band for metformin hydrochloride, along with quantification limits of 24.75 ng/band for lobeglitazone sulfate and 822.24 ng/band for metformin hydrochloride. The method demonstrated precision (% relative standard deviation of peak area <2) and accuracy (recovery between 96 and 103%). Conclusion: The suggested methodology is fit for the concurrent quantification of both drugs in tablet formulations, making it applicable for routine quality control assessments in laboratories.
- Open Access
- 30 August 2023
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 39 (4) , 970-975
Development of a Chromatographic Technique for Quantification of Drotaverine Hydrochloride and Diclofenac Potassium
Oriental Journal of Chemistry is a peer reviewed quarterly research journal of pure and applied chemistry. It publishes standard research papers in almost all thrust areas of current chemistry of academic and commercial importance. It provides a platform for rapid publication of quality research papers, reviews and chemistry letters. Oriental Journal of Chemistry is abstracted and indexed in almost all reputed National and International agencies.
- 30 August 2023
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 39 (4) , 970-975
Open AccessDevelopment of a Chromatographic Technique for Quantification of Drotaverine Hydrochloride and Diclofenac Potassium
Oriental Journal of Chemistry is a peer reviewed quarterly research journal of pure and applied chemistry. It publishes standard research papers in almost all thrust areas of current chemistry of academic and commercial importance. It provides a platform for rapid publication of quality research papers, reviews and chemistry letters. Oriental Journal of Chemistry is abstracted and indexed in almost all reputed National and International agencies.
- 30 July 2022
- Published by Informatics Publishing Limited in Journal of Natural Remedies
- p. 330-346
Catechins and Theaflavins: An Overview on Therapeutic Application
Flavonoids are a sort of natural substance which are basically plant secondary metabolites having a polyphenolic structure present in a wide range of food products. Flavonoids have become a vital constituent in nutraceutical, pharmacological, therapeutic, and cosmetic fields. This is owing to their capability to regulate essential cellular enzyme activity along with anti-cancer, anti-oxidative, anti-mutagenic, and anti-inflammatory effects. Through the revelation of a minimal cardiovascular death rate and the deterrence of CHD, research on flavonoids has gotten a boost. The functional mechanisms of flavonoids are still not completely known. Molecular docking and bioinformatics information are also been used to forecast potential flavonoid functions. Flavonoids are divided into several categories. Catechins and Theaflavins (TF’s) are two types of flavonoids that have been discussed in this review. ROS scavenging property of tea catechins and polyphenols have been demonstrated in vitro, and they may also serve as indirect antioxidants via their influence on transcription features and enzyme actions. There are a number of antioxidant polyphenols called collectively as “theaflavins” that are produced during the enzymatic oxidation (sometimes referred to mistakenly as “fermentation”) of black tea leaves by flavan-3-ol condensation Theaflavin-3-gallate, theaflavin-3’-gallate, and theaflavin-3-3’-digallate are the major theaflavins.
- 30 July 2022
- Published by Informatics Publishing Limited in Journal of Natural Remedies
- p. 330-346
Catechins and Theaflavins: An Overview on Therapeutic Application
Flavonoids are a sort of natural substance which are basically plant secondary metabolites having a polyphenolic structure present in a wide range of food products. Flavonoids have become a vital constituent in nutraceutical, pharmacological, therapeutic, and cosmetic fields. This is owing to their capability to regulate essential cellular enzyme activity along with anti-cancer, anti-oxidative, anti-mutagenic, and anti-inflammatory effects. Through the revelation of a minimal cardiovascular death rate and the deterrence of CHD, research on flavonoids has gotten a boost. The functional mechanisms of flavonoids are still not completely known. Molecular docking and bioinformatics information are also been used to forecast potential flavonoid functions. Flavonoids are divided into several categories. Catechins and Theaflavins (TF’s) are two types of flavonoids that have been discussed in this review. ROS scavenging property of tea catechins and polyphenols have been demonstrated in vitro, and they may also serve as indirect antioxidants via their influence on transcription features and enzyme actions. There are a number of antioxidant polyphenols called collectively as “theaflavins” that are produced during the enzymatic oxidation (sometimes referred to mistakenly as “fermentation”) of black tea leaves by flavan-3-ol condensation Theaflavin-3-gallate, theaflavin-3’-gallate, and theaflavin-3-3’-digallate are the major theaflavins.
- 30 July 2022
- Published by Informatics Publishing Limited in Journal of Natural Remedies
- p. 440-448
Spectrophotometric Methods for the Analysis of Berberine Hydrochloride and Eugenol in Formulated Emulgel
The present work describes three spectrophotometric methods for determining two phytoconstituent berberine hydrochloride and eugenol in formulated gels: simultaneous equation method, absorbance correction, and zero-crossing derivative method. In the simultaneous equation method, the absorbance at 263 nm and 280 nm and the absorbance correction method at 345 nm and 280 nm were measured and applied to their respective equation for the estimation of berberine hydrochloride and eugenol in phosphate buffer and formulated emulgel. The amplitudes of the first derivative spectra were measured at 252.5 nm for berberine hydrochloride and 263.5 nm for eugenol in zero-crossing crossing derivative spectrophotometry. For berberine hydrochloride and eugenol, linearity was attained in the concentration ranges of 4–20 and 2–10 µg/ml, respectively. Validation shows the applicability of the above procedures for the quantitative determination of berberine hydrochloride and eugenol. As a result, the presented method sucessfully estimated the aforesaid active phytoconstituent in formulated emulgel, with no interference from excipients.
- 30 July 2022
- Published by Informatics Publishing Limited in Journal of Natural Remedies
- p. 440-448
Spectrophotometric Methods for the Analysis of Berberine Hydrochloride and Eugenol in Formulated Emulgel
The present work describes three spectrophotometric methods for determining two phytoconstituent berberine hydrochloride and eugenol in formulated gels: simultaneous equation method, absorbance correction, and zero-crossing derivative method. In the simultaneous equation method, the absorbance at 263 nm and 280 nm and the absorbance correction method at 345 nm and 280 nm were measured and applied to their respective equation for the estimation of berberine hydrochloride and eugenol in phosphate buffer and formulated emulgel. The amplitudes of the first derivative spectra were measured at 252.5 nm for berberine hydrochloride and 263.5 nm for eugenol in zero-crossing crossing derivative spectrophotometry. For berberine hydrochloride and eugenol, linearity was attained in the concentration ranges of 4–20 and 2–10 µg/ml, respectively. Validation shows the applicability of the above procedures for the quantitative determination of berberine hydrochloride and eugenol. As a result, the presented method sucessfully estimated the aforesaid active phytoconstituent in formulated emulgel, with no interference from excipients.